The 2021/22 National Tariff Payment System came into effect in England

12

Oct 2021

On September 30, 2021, the 2020/21 National Tariff Payment System (NTPS) was published in England and came into effect on October 01, 2021. The NTPS is used by commissioners and providers of secondary healthcare. It sets the rules and prices that commissioners use to pay providers (such as acute hospital trusts) for NHS services.

2021/22 NTPS introduced the new aligned payment and incentive model for all secondary care and removed almost all national prices. The most published prices are now "unit prices", which are not mandatory, and National prices continue to apply to diagnostic imaging services only.

Some key changes in the new payment model are outlined below:

  • The aligned payment and incentive approach became the central part of the National Tariff. It is a combination of fixed (global budget) and variable (activity/quality-based) funding;
  • The role of HRG is now limited to cases when the new model does not apply (e.g., providers outside the regular responsibilities of CCGs with the amount of contract less than £10 million) and for a flexible component of the novel system (e.g., for excess care, which will be paid using 50% of national HRG tariff);
  • From 2021/22, there are no separate innovation payment options.
  • The innovative products list (Annex A, tab 14c) includes technologies supported by MedTech Funding Mandate. These products have to be implemented by commissioners and reimbursed under local pricing arrangements;
  • There have been no principal policy changes for the Best Practice Tariff (BPT). The day case and outpatient procedures BPTs were discontinued.

In addition, as part of the response to Covid-19, the NHS has adopted special payment arrangements for 2021/22. Under these arrangements, most providers and commissioners have moved to block contract payments "on-account." The guidance on payment and contracting for these arrangements is available here.

See the full details here.

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). First EU issues of both newsletters are available for download free-of-charge.

Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks).

The latest related news

23

Mar 2022

In late January 2022, Swedish Medical Technologies Product (MTP) Council issued an updated version of recommendations regarding gene expression analysis for decision-making on the adjuvant breast cancer treatment, initially published in November 2021. The recommendation to the regions remains the same. The changes were only concerned with the clarification of some facts.

Read more

21

Mar 2022

The NHS Insights Prioritisation Programme (NIPP) is commissioned by the NHS Accelerated Access Collaborative (AAC) and the National Institute for Health Research (NIHR). It is designed to accelerate the evaluation and implementation of innovation that supports post-pandemic ways of working, builds service resilience, and delivers benefits to patients. Fourteen projects have been funded and have now commenced activity that will be ongoing until March 2023.

Read more

18

Mar 2022

On February 22, 2022, a repository of innovative acts outside the nomenclature of biology and anatomopathology (RIHN) and a Supplementary list of IVD tests were published. Minor changes were introduced in the 2022 RIHN list.

Read more

16

Mar 2022

In February 2022, Swedish Medical Technologies Product (MTP) Council issued an updated recommendation on FreeStyle Libre for continuous glucose monitoring in type 2 diabetes (T2D). The initial recommendations were published by NT Council in 2018 and updated by MTP Council in 2020 to include FreeStyle Libre 2. In the 2022 update, MTP Council decreased the Hba1c limit from 70 to 60 mmol/mol and added a statement on lifestyle changes and treatment optimization with non-insulin antidiabetic drugs.

Read more

14

Mar 2022

In February 2021, the Clinical Coding and Schedule Development (CCSD) working group, which develops and maintains procedural and diagnostics nomenclature for private payers in England, published Bulletins 0182 and 0079 with changes to be implemented no later than April 10, 2022. Three new procedure codes concerned robotic surgery in orthopaedic area, spinal procedures, and ophthalmology, and five new diagnostic codes were introduced.

Read more